Second cancers in Hodgkin's lymphoma long-term survivals: A
60-year single institutional experience with real-life cohort
of 871 patients

J 2018

Second cancers in Hodgkin's lymphoma long-term survivals: A 60-year single institutional experience with real-life cohort of 871 patients

PETRÁKOVÁ, Katarína, Jiří VYSKOČIL, Peter GRELL, Ondřej MÁJEK, Renata SOUMAROVÁ et. al.

Basic information

Original name

Second cancers in Hodgkin's lymphoma long-term survivals: A 60-year single institutional experience with real-life cohort of 871 patients

Authors

PETRÁKOVÁ, Katarína (203 Czech Republic, belonging to the institution), Jiří VYSKOČIL (203 Czech Republic), Peter GRELL (703 Slovakia, belonging to the institution), Ondřej MÁJEK (203 Czech Republic, belonging to the institution), Renata SOUMAROVÁ (203 Czech Republic), Jiri NOVAK (203 Czech Republic), Petr BURKOŇ (203 Czech Republic, belonging to the institution), Zdeněk KRÁL (203 Czech Republic), Tomáš KAZDA (203 Czech Republic, guarantor, belonging to the institution) and Rostislav VYZULA (203 Czech Republic, belonging to the institution)

Edition

International Journal of Clinical Practice, HOBOKEN, Medicom International, 2018, 1368-5031

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.613

RIV identification code

RIV/00216224:14110/18:00104491

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1111/ijcp.13235

UT WoS

000441884600001

Keywords in English

Hodgkin's lymphoma

Abstract

V originále

Background and Purpose: Appropriate surveillance guidelines for patients after successful treatment of Hodgkin's lymphoma (HL) are needed to reduce mortality of iatrogenic secondary cancers (SC). This large single institutional retrospective study analyses the risk of SC in HL patients treated outside of clinical trials over past decades. Material and Methods: Consecutive series of HL patients were analysed with median follow-up 12years. Standardised incidence ratio (SIR) and absolute excess risk (AER) were calculated for site-specific risk of SC. Results: In total of 871 patients (491 men; median age 34years), chemotherapy alone, radiotherapy alone, and combined treatment underwent 36%, 40%, and 24% patients. 154 SC were found with significantly increased SIR=2.9 and AER=80.8 for all cancers except of nonmelanoma-skin cancer. SC-related death occurred in 71 patients (15% of those who died, 8% of whole cohort). The most common SC were lung (17.5% of all malignancies, SIR=3.2), breast carcinoma (15.6%, SIR=4.4), and haematological malignancy (non-Hodgkin's lymphoma SIR=13.1; leukaemia SIR=5.8). For SC within radiation field, the highest AER was in breast (AER=46.9), colorectal (AER=22.8), and lung cancer (AER=17). Conclusions: Patients with HL are generally at great risk of developing SC, which is significantly increased especially by the use of radiotherapy. We suggested special follow-up schema for patients after initial HL treatment suitable for daily real-world clinical practice. The system depends on gender, form of HL treatment and especially the form of radiation therapy in terms of location of radiation fields.

Links

LQ1601, research and development project

Name: CEITEC 2020 (Acronym: CEITEC2020)

Investor: Ministry of Education, Youth and Sports of the CR

Citovat

PETRÁKOVÁ, Katarína, Jiří VYSKOČIL, Peter GRELL, Ondřej MÁJEK, Renata SOUMAROVÁ, Jiri NOVAK, Petr BURKOŇ, Zdeněk KRÁL, Tomáš KAZDA and Rostislav VYZULA. Second cancers in Hodgkin's lymphoma long-term survivals: A 60-year single institutional experience with real-life cohort of 871 patients (Second cancers in Hodgkin’s lymphoma long- term survivals: A 60- year single institutional experience with real- life cohort of 871 patients). International Journal of Clinical Practice. HOBOKEN: Medicom International, 2018, vol. 72, No 9, p. 1-9. ISSN 1368-5031. Available from: https://dx.doi.org/10.1111/ijcp.13235.

@article{1468657,
   author = {Petráková, Katarína and Vyskočil, Jiří and Grell, Peter and Májek, Ondřej and Soumarová, Renata and Novak, Jiri and Burkoň, Petr and Král, Zdeněk and Kazda, Tomáš and Vyzula, Rostislav},
   article_location = {HOBOKEN},
   article_number = {9},
   doi = {http://dx.doi.org/10.1111/ijcp.13235},
   keywords = {Hodgkin's lymphoma},
   language = {eng},
   issn = {1368-5031},
   journal = {International Journal of Clinical Practice},
   title = {Second cancers in Hodgkin's lymphoma long-term survivals: A 60-year single institutional experience with real-life cohort of 871 patients},
   volume = {72},
   year = {2018}
}

TY  - JOUR
ID  - 1468657
AU  - Petráková, Katarína - Vyskočil, Jiří - Grell, Peter - Májek, Ondřej - Soumarová, Renata - Novak, Jiri - Burkoň, Petr - Král, Zdeněk - Kazda, Tomáš - Vyzula, Rostislav
PY  - 2018
TI  - Second cancers in Hodgkin's lymphoma long-term survivals: A 60-year single institutional experience with real-life cohort of 871 patients
JF  - International Journal of Clinical Practice
VL  - 72
IS  - 9
SP  - 1-9
EP  - 1-9
PB  - Medicom International
SN  - 13685031
KW  - Hodgkin's lymphoma
N2  - Background and Purpose: Appropriate surveillance guidelines for patients after successful treatment of Hodgkin's lymphoma (HL) are needed to reduce mortality of iatrogenic secondary cancers (SC). This large single institutional retrospective study analyses the risk of SC in HL patients treated outside of clinical trials over past decades. Material and Methods: Consecutive series of HL patients were analysed with median follow-up 12years. Standardised incidence ratio (SIR) and absolute excess risk (AER) were calculated for site-specific risk of SC. Results: In total of 871 patients (491 men; median age 34years), chemotherapy alone, radiotherapy alone, and combined treatment underwent 36%, 40%, and 24% patients. 154 SC were found with significantly increased SIR=2.9 and AER=80.8 for all cancers except of nonmelanoma-skin cancer. SC-related death occurred in 71 patients (15% of those who died, 8% of whole cohort). The most common SC were lung (17.5% of all malignancies, SIR=3.2), breast carcinoma (15.6%, SIR=4.4), and haematological malignancy (non-Hodgkin's lymphoma SIR=13.1; leukaemia SIR=5.8). For SC within radiation field, the highest AER was in breast (AER=46.9), colorectal (AER=22.8), and lung cancer (AER=17). Conclusions: Patients with HL are generally at great risk of developing SC, which is significantly increased especially by the use of radiotherapy. We suggested special follow-up schema for patients after initial HL treatment suitable for daily real-world clinical practice. The system depends on gender, form of HL treatment and especially the form of radiation therapy in terms of location of radiation fields.
ER  -

PETRÁKOVÁ, Katarína, Jiří VYSKOČIL, Peter GRELL, Ondřej MÁJEK, Renata SOUMAROVÁ, Jiri NOVAK, Petr BURKOŇ, Zdeněk KRÁL, Tomáš KAZDA and Rostislav VYZULA. Second cancers in Hodgkin's lymphoma long-term survivals: A 60-year single institutional experience with real-life cohort of 871 patients (Second cancers in Hodgkin’s lymphoma long- term survivals: A 60- year single institutional experience with real- life cohort of 871 patients). \textit{International Journal of Clinical Practice}. HOBOKEN: Medicom International, 2018, vol.~72, No~9, p.~1-9. ISSN~1368-5031. Available from: https://dx.doi.org/10.1111/ijcp.13235.

Detailed Information on Publication Record